Filing Flows › Ardelyx (ARDX) › Q3 2026 › vs Q2 2026
Ardelyx (ARDX) Q3 2026 vs Q2 2026 (quarter over quarter)
Ardelyx's revenue rose $6.8M (+6%) from $121M in Q2 2026 to $128M in Q3 2026. The biggest changes: Product sales, net +$7.3M (+6%); Product supply revenue −$596K (-30%); Non-cash royalty revenue related to the sale of future royalties −$72K (-11%).
Ardelyx, Q3 2026: revenue $128M (+16% year over year), operating margin 3.2%, net loss $737K, operating cash flow $2.2M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| IBSRELA | $96.3M | $86.2M | $10.0M | +12% |
| XPHOZAH | $29.2M | $31.9M | −$2.7M | -9% |
| Product sales, net | $125M | $118M | $7.3M | +6% |
| Product supply revenue | $1.4M | $2.0M | −$596K | -30% |
| Non-cash royalty revenue related to the sale of future royalties | $604K | $676K | −$72K | -11% |
| Revenue | $128M | $121M | $6.8M | +6% |
| Net loss | $737K | $16.7M | −$16.0M | -96% |
| Costs & expenses | $128M | $138M | −$9.2M | -7% |
| Operating costs | $124M | $133M | −$9.7M | -7% |
| Interest & other, net | $4.7M | $4.2M | $484K | +12% |
| Income tax | $90K | $110K | −$20K | -18% |
| Cost of revenue | $4.5M | $5.8M | −$1.2M | -21% |
| Research & development | $25.2M | $26.1M | −$904K | -3% |
| SG&A | $93.9M | $101M | −$7.5M | -7% |
| Operating cash sources | $15.7M | $15.9M | −$198K | -1% |
| Depreciation & amortization | $621K | $604K | $17K | +3% |
| Share-based compensation | $15.1M | $15.3M | −$215K | -1% |
| Net loss absorbed | $737K | $16.7M | −$16.0M | -96% |
| Working capital & other | $12.8M | $5.6M | $7.2M | +129% |
| Operating cash flow | $2.2M | −$6.4M | $8.6M | — |
Questions
How much did Ardelyx's revenue grow quarter over quarter in Q3 2026?
Ardelyx's revenue rose $6.8M (+6%) from $121M in Q2 2026 to $128M in Q3 2026.
What drove Ardelyx's revenue change in Q3 2026?
Product sales, net +$7.3M (+6%); Product supply revenue −$596K (-30%); Non-cash royalty revenue related to the sale of future royalties −$72K (-11%).